State Pharmaceuticals Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: State Pharmaceuticals Pharmaceutical Import Records from India — 2 Products, $610.4K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

State Pharmaceuticals — Pharmaceutical Importer Profile (2026) | 2 Products, $610.4K Trade | TransData Nexus

State Pharmaceuticals

Pharmaceutical Importer · Sri Lanka · Respiratory Focus · $610.4K Total Trade · DGFT Verified

State Pharmaceuticals is a pharmaceutical importer based in Sri Lanka with a total trade value of $610.4K across 2 products in 2 therapeutic categories. Based on 18 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. State Pharmaceuticals sources from 122 verified Indian suppliers, with Zydus Lifesciences Limited accounting for 12.9% of imports.

State Pharmaceuticals — Import Portfolio & Supplier Network

State Pharmaceuticals import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to State Pharmaceuticals?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zydus Lifesciences Limited	$3.9M	163	12.9%
Alvita Pharma Private Limited	$1.9M	69	6.5%
Reliance Life Sciences Private Limited

What Formulations Does State Pharmaceuticals Import?

Formulation	Value	Ships
Human normal immunoglobulin for	$450.0K	9
Diagnostic kits meriscreen dengue ns1	$350.0K	7
Raksharab 10 ML(veterinary rabies	$300.0K	6
Pharmaceutical finished formulation clindabact-150 (clindamycin injection BP 150MG/ML), 10 x 2 ML ampoules,e, sri	$290.5K	16
Sevoflurane 250ML other desc.as per	$250.0K	5
Pharmaceutical products glytad	$250.0K	5
Nicardia retard 20MG 5x10t srl exp -	$243.0K	5
Acecloright (aceclofenac tablets 100MG	$218.2K	9
Elastic adhesive bandage b.p. 1993	$209.2K	6
Morphine sulphate INJ BP 2MG/2ML	$200.0K	4
Clopid (clopidogrel tablets USP 75 MG )	$200.0K	4
Clopid (clopidogrel tablets USP 75 MG)	$200.0K	4
63619 packs of gliclazide modified	$200.0K	4
Isoflurane 250ML other desc.as per inv green card no.420/vsez	$200.0K	4
Phenylephrine INJ BP 10MG/ML,1ML	$194.5K	4

State Pharmaceuticals imports 766 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Theophylline	Respiratory	$316.1K	10	2.0%	12
2	Isosorbide	Cardiovascular	$294.3K	8	0.7%	15

State Pharmaceuticals imports 2 pharmaceutical products across 2 categories into Sri Lanka totaling $610.4K.

State Pharmaceuticals — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

State Pharmaceuticals Corporation (SPC) is a state-owned enterprise headquartered in Colombo, Sri Lanka. Established in 1971 under the State Industrial Corporations Act Number 49 of 1957, SPC was founded following the recommendations of the Bibile–Wickramasinghe Commission, which aimed to make pharmaceuticals more affordable and accessible in Sri Lanka. The corporation's mission is to provide quality-assured health care items that are safe and effective, at an affordable price, while educating the public on the rational use of drugs. (spc.lk)

SPC serves as the largest supplier of pharmaceuticals, surgical consumables, laboratory chemicals, and equipment in Sri Lanka. It is the sole provider to all institutions under the Ministry of Health and also supplies the private sector, holding a 30% market share. The corporation operates a network of retail outlets known as Rajya Osu Salas (state drug shops), with 18 locations, and collaborates with 36 franchise outlets, 48 distributors, and 20 authorized retailers nationwide.

2Distribution Network

SPC's distribution network is extensive, ensuring nationwide coverage across Sri Lanka. The corporation's retail outlets, Rajya Osu Salas, are strategically located to provide easy access to essential medications for the public. Additionally, SPC's collaboration with numerous franchise outlets, distributors, and authorized retailers further strengthens its reach, facilitating the efficient distribution of pharmaceutical products throughout the country.

3Industry Role

In Sri Lanka's pharmaceutical supply chain, SPC plays a pivotal role as the primary wholesaler and government procurement agency. By centralizing the procurement and distribution of pharmaceuticals, SPC ensures the availability of essential medicines to both public and private healthcare sectors. Its operations are integral to maintaining the stability and affordability of the pharmaceutical market in Sri Lanka.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — State Pharmaceuticals

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

SPC's sourcing strategy exhibits a high degree of concentration, with a portfolio consisting solely of two imported products: Theophylline and Isosorbide, accounting for 100% of its imports from India. This singular focus on these two products suggests a strategic choice to streamline procurement and ensure consistent supply. However, this concentration also poses risks, such as potential supply chain disruptions or price fluctuations affecting these specific products. The shipment data indicates a stable relationship with Indian suppliers, as evidenced by the consistent import volumes over the years. Nonetheless, the lack of diversification in the product portfolio may limit SPC's ability to adapt to changing market demands or therapeutic needs.

2Supply Chain Resilience

SPC's supply chain resilience is closely tied to its exclusive reliance on Indian suppliers for Theophylline and Isosorbide. The absence of backup suppliers for these products indicates a potential vulnerability to supply disruptions. The limited diversity in imported formulations further constrains the corporation's ability to respond to shifts in therapeutic requirements or market dynamics. Additionally, the concentration of shipments from a select group of suppliers may expose SPC to risks associated with geopolitical tensions or regulatory changes affecting trade relations between Sri Lanka and India.

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing the pharmaceutical sector in Sri Lanka. Established in 2015 through the National Medicines Regulatory Authority Act, No. 5 of 2015, the NMRA is responsible for ensuring the safety, efficacy, and quality of medicines, medical devices, and related products. The authority regulates the manufacturing, importation, distribution, and sale of medicines, as well as clinical trials conducted within the country. (nmra.gov.lk)

2Import Licensing & GMP

Importers of pharmaceutical products into Sri Lanka must obtain the necessary import licenses from the NMRA, ensuring compliance with the country's regulatory standards. The NMRA recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers are required to ensure that their suppliers adhere to these GMP standards to guarantee the quality and safety of imported medicines. (nmra.gov.lk)

3Quality & Labeling

State Pharmaceuticals — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

SPC's focus on importing Theophylline and Isosorbide indicates a strategic emphasis on respiratory and cardiovascular therapeutic areas. This specialization suggests a targeted approach to meet specific patient needs within these domains. The market demand for these products is likely driven by the prevalence of respiratory and cardiovascular conditions in Sri Lanka, necessitating a reliable supply of effective treatments.

2Sourcing Profile

SPC's sourcing strategy is centered on generic drug imports, primarily from India, reflecting a cost-effective approach to procurement. The corporation's preference for specific formulations, such as Theophylline and Isosorbide, aligns with its focus on particular therapeutic areas. India's established pharmaceutical manufacturing capabilities and competitive pricing make it a suitable partner for SPC's procurement needs.

3Market Positioning

By concentrating on respiratory and cardiovascular products, SPC serves a niche segment of the Sri Lankan pharmaceutical market. Its role as a primary wholesaler and government supplier positions it to meet the needs of public healthcare institutions and private sector entities requiring these specialized medications.

Seller's Guide — How to Become a Supplier to State Pharmaceuticals

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a potential opportunity for new Indian suppliers to enter the Sri Lankan market by offering alternative products in the respiratory and cardiovascular categories. Diversifying SPC's product portfolio could enhance its competitiveness and resilience. Identifying gaps in SPC's current sourcing, such as the need for additional formulations or dosage forms, presents avenues for collaboration and market expansion.

2Requirements & Qualifications

Indian exporters aiming to supply SPC must ensure their products comply with NMRA's regulatory standards, including GMP certifications recognized by WHO or PIC/S. Products must undergo quality testing by the NMQAL and meet labeling requirements in Sinhala and Tamil. Additionally, adherence to serialization mandates is necessary to facilitate traceability and ensure product authenticity.

3How to Approach

To establish a relationship with SPC, Indian exporters should initiate contact through formal channels, providing detailed product information and demonstrating compliance with NMRA standards. Participating in SPC's tender processes and submitting the required documentation can facilitate entry into the Sri Lankan market. Understanding the regulatory filing requirements and timelines is crucial for successful market entry.

Frequently Asked Questions — State Pharmaceuticals

What products does State Pharmaceuticals import from India?

State Pharmaceuticals imports 2 pharmaceutical products across 2 categories. Top imports: Theophylline ($316.1K), Isosorbide ($294.3K).

Who supplies pharmaceuticals to State Pharmaceuticals from India?

State Pharmaceuticals sources from 122 verified Indian suppliers. The primary supplier is Zydus Lifesciences Limited (12.9% of imports, $3.9M).

What is State Pharmaceuticals's total pharmaceutical import value?

State Pharmaceuticals's total pharmaceutical import value from India is $610.4K, based on 18 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does State Pharmaceuticals focus on?

State Pharmaceuticals imports across 2 categories. The largest: Respiratory (51.8%), Cardiovascular (48.2%).

Get Full State Pharmaceuticals Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.